Lumos Diagnostics (ASX:LDX) Announces Q4 FY25 Financial Results and Major Distribution Agreement
Lumos Diagnostics (ASX:LDX) reports Q4 FY25 revenue of US$2.6M, secures major US distribution deal, and advances FebriDx CLIA waiver study.
Category: ASX-LDX
Lumos Diagnostics
Lumos Diagnostics (ASX:LDX) Secures Largest FebriDx Purchase Order with iMedical
Lumos Diagnostics (ASX:LDX) announces its largest purchase order for FebriDx, reflecting increased US adoption and market acceptance.
Lumos Diagnostics (ASX:LDX) Secures Additional Medicare Coverage
Lumos Diagnostics (ASX:LDX) expands Medicare reimbursement for FebriDx to over 55% of US coverage, enhancing market access.